Anti-Human IL-17A Reference Antibody (Xeligekimab, RUO) (HS856116)

Name: Anti-Human IL-17A Reference Antibody (Xeligekimab, RUO)
Brand: abinScience
SKU: HS856116
Price: 176 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	HS856116
설명	Xeligekimab (HS856116) is a research-grade recombinant antibody targeting CTLA-8. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
종 반응성	Human
응용 분야	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
숙주 종	Human
클론성	Monoclonal
이소타입	IgG4-kappa
테스트된 응용 분야	WB
타겟	CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A
내독소 수준	< 10 EU/mg
순도	>95% as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	Q16552
형태	Liquid
저장 완충액	0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
대체 이름	GR1501, GR-1501, GR15012382921-73-3
배경	Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx). 1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361 2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633 3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971 4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828 5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122 6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080
참고사항	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207)

이미지

SDS-PAGE

SDS-PAGE for Research Grade Xeligekimab.
Bioactivity

Detects recombinant human IL17A (Catalog No: HS856011) in indirect ELISA
Western blot

Western blot analysis was performed using anti-IL17A monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL17A (Catalog No: HS856012)
Lane 2: negative control